Ann: First Clinical Data announced from 90mg Dosing of Efti, page-53

Okay ydcaq, we have been informed that if we get very strong data in the tacti003 ph2b trial that this trial alone could leave to accelerated approval,and you have been kind enough to explain why this couldn’t be the case for tacti004,whilst the company already has fast track approval in Tacti 004 , do you think if the criteria is met that the upcoming tacti004 registrational trial could additionally receive breakthrough designation , as it is my understanding from my readings that this is relatively common?

“tt is not uncommon for a drug with Fast Track Designation to be granted Breakthrough Therapy Designation during the drug development process.”

”Break through designation additionally to fast track designation allows for;Eligibility for Rolling Review and Priority Review if relevant criteria are met.”